Targeted Therapies in Advanced Renal Cell Carcinoma

Download Podcast

Listen to MP3

Podcast Evaluation

A presentation from the NCCN 13^th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care™ held in Hollywood, Florida.

Presenter

Timothy M. Kuzel, MD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Chicago, Illinois
                                   
Faculty Disclosure Statement

Dr. Kuzel has disclosed that he has financial interests, arrangements, or affiliations with the manufacturer of products or devices to be discussed in this activity or who may financially support the activity. He has received grant/research support from Genentech, Inc. and has served as a scientific advisor for Wyeth Pharmaceuticals. He has also served on the product/speakers’ bureau for Bayer HealthCare, Pfizer Inc., and Wyeth Pharmaceuticals.

Dr. Kuzel has indicated that his presentation will not include discussion of investigational or unlabeled uses of commercial products.

Program Goal

The goal of this program is to provide participants with increased knowledge regarding the innovative therapies and treatment methods used for the management of patients with advanced renal cell carcinoma (RCC).

Educational Objectives

Following this activity, participants should be able to:

• List targeted therapies available for the treatment of advanced RCC
• Discuss the clinical application of targeted therapies in the treatment of advanced RCC
• Identify appropriate patients with advanced RCC for treatment with targeted therapies
• Explain side effects associated with the use of targeted therapies in patients with advanced RCC

Intended Audience

This educational activity is designed to meet the educational needs of physicians, nurses, and other clinical professionals who manage patients with cancer.

Activity Instructions

Continuing education credit will be awarded to participants who listen to the presentation and complete the evaluation.  Participants should review the learning objectives and faculty disclosure statement prior to listening to a presentation in its entirety.  You must be connected to the Internet in order to review and complete the evaluation form.  A statement of credit will be electronically generated once you complete the evaluation form.  To receive credit, this activity must be completed no later than May 19, 2009.  There is no fee for participating in this activity.

Download Podcast

Listen to MP3

Podcast Evaluation

Accreditation Information

Physicians

The National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NCCN designates this educational activity for a maximum of 0.75 AMA PRA Category 1
Credit(s)™.  Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses

This activity is approved for 0.8 contact hours. National Comprehensive Cancer Network is an approved provider of continuing nursing education by the PA State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

Approval as a provider refers to recognition of educational activities only and does not imply ANCC Commission on Accreditation or PA Nurses approval or endorsement of any product.

Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity.

Release date:  May 19, 2008
Expiration date:  May 19, 2009

Commercial Support

Supported by an unrestricted educational grant from Wyeth